Table 8 Multivariate analysis of patient prognosis in metastatic breast cancer
From: Site-specific metabolic phenotypes in metastatic breast cancer
Parameters | Overall survival | ||
|---|---|---|---|
Hazard ratio | 95% CI | P-value | |
ER status | Â | Â | 0.067 |
  Negative versus positive | 10.42 | 0.846-128.4 |  |
PR status | Â | Â | 0.091 |
  Negative versus positive | 1.195 | 0.898-4.237 |  |
HER2 status | Â | Â | 0.408 |
  Negative versus positive | 0.436 | 0.075-2.869 |  |
Ki-67 LI | Â | Â | 0.002 |
  ≤14 versus >14 | 4.096 | 1.664-10.08 |  |
Tumor phenotypes | Â | Â | 0.147 |
  Luminal A |  |  |  |
  Luminal B | 6.697 | 0.387-116.0 |  |
  HER2 | 7.286 | 0.348-152.4 |  |
  TNBC | 0.433 | 0.055-3.387 |  |
CAIX | Â | Â | 0.189 |
  Negative versus positive | 1.690 | 0.773-3.695 |  |
PSPH | Â | Â | 0.117 |
  Negative versus positive | 2.156 | 0.825-5.634 |  |
SHMT1 | Â | Â | 0.014 |
  Negative versus positive | 2.836 | 1.239-6.495 |  |
Serine/glycine type | Â | Â | 0.451 |
  No versus Yes | 0.723 | 0.311-1.679 |  |